ZOMDF ZOMEDICA CORP

OTC
$0.08

ZOMEDICA CORP Q3 F2026 Earnings Call Transcript

AI Conference Call Analysis

Sign in or subscribe to read.
Mike Bridavsky
Pet owner
to actually get her bone to heal.
Unknown
Pet owner
She's doing so good. She's like a different dog. It's crazy. Yeah.
Unknown
Veterinary professional
The reason we love, all our doctors love PulseFed is that there's a lot of body of evidence supporting this treatment. Why my customers and clients like it is that it's non-invasive and I can keep sport horses going without injections, especially my metabolic ones. I've got several metabolic horses that don't tolerate, even some biologics don't respond nearly as well as I do to shockwave. The other great thing is for obviously rehab and injuries. I love the initial protocols. We get a quick response without being invasive. So I love and trust PulseFed and all their products.
Unknown
Veterinary professional
We've had a pulse bed shock wave for three years now. We use it for cases of biceps tendinopathy, iliopsoas injuries, arthritis of every joint, as well as lumbosacral disease. We use it almost every day in practice because of the benefits that we see, and I wouldn't be able to practice without it.
Unknown
Veterinary professional
PulseVet, which is shockwave technology. It encourages vasodilation and allows all those good healthy cells to come into the area and it promotes pain relief. It helps with inflammation. It's really good for chronic pain. It's good for osteoarthritis, tendon ligament injuries, post-surgical pain, or even like granulomas.
Mike Bridavsky
Pet owner
This is my very special cat, Little Bo. Over time, over the first year of her life, I noticed gradually that that was becoming increasingly hard for her to do. She wasn't getting around like she used to. She was almost unable to get around on her own. I took her to my vet, and it was determined that she had an extraordinarily rare bone condition called osteopetrosis, and she was completely immobile. The specialist actually only gave her a few months. And so one fan had sent me a message who said that their neighbor had an older dog with arthritis and was using this device called the Assisi Loop, and that it helped quite a bit. I talked to my vet, and he had one prescribed. The improvements were noticeable and immediate. Within a week, she was standing upright. Two to three weeks, she started walking normally. Five to six months, she started climbing stairs, and now she even runs. Totally certain that this is thanks to the Assisi Loop. She's been using it for almost five years.
Unknown
Pet owner
And this is Max, who has a genetic problem with his bones. He has a curved spine and deformed elbows and knees bones, which caused him to be paralyzed from the waist down. The doctor suggested to put him to sleep since he will continue to be in pain. Mike, who is the owner of Little Bob, suggested that CC Loop. So I ordered it, I tried it, and for my surprise, after a little while, he started moving his legs again. And all the doctors were surprised. We don't know how this happened, but my baby is now walking again.
Unknown
Pet owner
This is my cat, Daisy. Five years ago, when she was about 11 or 12, she started having really bad arthritis. We went in and had some x-rays done and it showed that her hips were very arthritic. Our veterinarian told us about the loop and we were very, very happy to start using it. We apply to
Unknown
Veterinary professional
We took a hefty dose of the VETA gel into two incisions and within a matter of 30 seconds or so, the bleeding did subside. We were able to achieve hemostasis and got a good visual representation of the surgical sites. Within maybe 24 or 48 hours, the client did report that the dog was walking on its paw pad like as if nothing ever happened.
Unknown
Veterinary professional
The MetaGel was able to fill in all the nooks and crannies and just with a light application of gauze over the top, just gently pushing down, it filled everything, waited a couple minutes and easily suctioned everything back out and cleaned everything up. The hemorrhage was gone. Definitely, I think any spinal fracture, any spinal surgery or any brain surgery that's going to Potentially ooze, absolutely. I think you could easily use this, fill the gaps in minimal time. And that's kind of the thing that impressed me. It was just one application and that was basically done.
Unknown
Veterinary professional
Especially for puncture wounds, what we did was take gauze and stuff it into that puncture wound, which does require compression over that area. With Veta-Gel, we can put it right into that puncture hole, we can put it right into that bullet hole, we can put it right into that stab, we can deploy the entire syringe there and then not worry about continued bleeding from the area. It's not something where we need to rely on human compression to it in order for it to work, which allows for transportation, allows for moving that patient a lot easier.
Unknown
Webinar narrator/presenter
Welcome to Zomedica's 3rd Friday at 4 investor webinar. Today's session comes in two parts. First, we'll look at the people behind Zomedica's competitive edge. Then, Mike Zuehlke will walk through our 3rd quarter 2026 financial results. In animal health, technology can be matched over time, but experience, tenure, and deep knowledge of the veterinary market are much harder to copy.
Unknown
Webinar narrator/presenter
On today's webinar, you'll hear from the veterinarians, scientists, manufacturing leaders, finance professionals, and marketing and sales teams who build Zomedica's products and bring them to practices.
Unknown
Webinar narrator/presenter
Each of them represents one of Zomedica's seven guiding principles. From here, we'll cover Zomedica's mission and the five pillars framework, Hear from our CEO and then meet the team.
Unknown
Webinar narrator/presenter
Before we begin, I want to remind current and potential investors that we will be making various remarks about future expectations, plans, and prospects that are considered forward-looking statements. There are risks that actual results may differ from these statements. We refer you to the safe harbor statement on screen. Thank you for joining us for Zomedica's Investor Webinar Series. We're excited to have you with us as we take a closer look at our company, This series is designed to give you a deeper understanding of how we're delivering value to veterinarians and to our shareholders. At Zomedica, our mission is to deliver innovative diagnostic and therapeutic technologies that empower veterinarians to focus on what they love most, enhancing pet care and improving pet parent satisfaction. Equally important, we help vets with what they need most, streamlining workflow, increasing cash flow, and boosting practice profitability. At Zomedica, our mission is guided by what we call our five pillars. These are core objectives that shape every decision we make about products and innovation. First and foremost, we aim to improve the quality of care for the pets. Equally important is enhancing the satisfaction of the pet parent, ensuring they feel confident and comfortable with the care provided. Our solutions also focus heavily on improving the veterinarian's daily workflow, helping veterinary practices operate smoothly and efficiently. Additionally, we are committed to positively impacting veterinarian cash flow, making sure our offerings are financially accessible and beneficial. Finally, our ultimate goal is to increase veterinarian profitability, providing products and solutions that help veterinary clinics grow and thrive financially.
Unknown
Webinar narrator/presenter
As you meet today's team, keep the five pillars in mind because the people behind each guiding principle are the ones who deliver on them for the pet, the pet parent, and the practice.
Unknown
Webinar narrator/presenter
Now let's hear from Larry Heaton, Zomedica's Chief Executive Officer.
Larry Heaton
Chief Executive Officer
Good afternoon, everyone, and welcome. I'm Larry Heaton, the Chief Executive Officer of Zomedica. Thank you for joining us today for another fourth Friday at 4, only this month it's the third Friday at 4. Whether you are an investor, an analyst, or someone following our progress, we appreciate you taking the time to be here. Today's session focuses on the people behind Zomedica's competitive edge. Followed by a recap of our third quarter results and then Q&A. In animal health, the companies that lead are the ones closest to their customers, the veterinarians and their patients. And those relationships are built by people. Some of our people have worked in clinics. Some built our manufacturing operations from the ground up. Others have spent years learning technologies that simply can't be learned overnight. For a clinic, a customer, that means they see products that are shaped by real practice needs. For Zomedica, it's an advantage that customers can't easily replicate. We organize ourselves around seven guiding principles. They shape how our team makes decisions, how we build and support our products, and how a company of our size competes with much larger ones. They're not simply posters on a wall, it's how we operate. In the segment that follows, you'll hear from the people who live these principles every day across human resources, product, finance, research and development, manufacturing, marketing, and sales. Then, our Senior Vice President of Finance and Corporate Controller, Mike Zuehlke, will walk through our third quarter results. After that, we'll open it up for Q&A. So with that, I'll turn it over to Kristin Domanski, our Vice President of Human Resources, to introduce our seven guiding principles.
Kristin Domanski
Vice President of Human Resources
Hello, I'm Kristin Domanski, Vice President of Human Resources, and I've been here at Zomedica just about five years. Let's explore our guiding principles and what they mean to us here at Zomedica. It starts with reliance on each other. We depend on one another's expertise, share our strengths, and deliver on our commitments, knowing our success depends on the contributions of every team member across the organization. Next, customer obsession. We put customers at the center of what we do, listen closely to understand and anticipate their needs, and remain responsive and committed to their success. Financial discipline. We manage our resources responsibly, focus spending where it creates the most value, and make sound financial decisions that support sustainable growth. Innovative R&D. We challenge what is possible, applying curiosity, expertise, and fresh thinking to develop meaningful solutions that advance animal health. Quality manufacturing. We take pride in producing reliable, high-quality products with precision, consistency, and attention to every detail, maintaining rigorous standards from production through delivery. Creative marketing. We use creativity and insight to tell compelling stories, demonstrate the value of our products, engage customers, and create demand. And finally, tenacious selling. We pursue every opportunity with energy and determination, persist through challenges, build strong customer relationships, and stay focused on earning business and delivering results. These principles give us a shared lens for how we approach our work and make decisions. They help us focus on what matters most, make thoughtful choices, and take consistent action aligned with our priorities. Together, they provide a practical guide for how we put those priorities into practice and move the company forward. In a company our size, every person and every team matters to our success and we depend on one another to do our part and deliver on what others are counting on us to do. That reliance on one another extends across functions, allowing us to bring the right expertise together to get things done. This combination of accountability and collaboration helps us move quickly, adapt to change, and accomplish more than our size might suggest, giving us an important competitive edge.
Unknown
Webinar narrator/presenter
Zomedica brings together 140 talented people across the United States, including on-site facilities in Georgia, Michigan and Minnesota. Our team is nearly evenly represented by men and women, and its diversity is reflected in the 19 different languages spoken by employees across the company. A team that relies on each other can move faster than much larger competitors. Here's Christina Maness, Manager of Human Resources.
Christina Maness
Manager of Human Resources
Our guiding principles of customer obsession and reliance on each other work hand in hand. While we have different responsibilities, we share the same goal. By working collaboratively, we accomplish more and deliver better results for customers. It reinforces that success is not just about what we achieve individually or within our own departments, but what we accomplish together as one team.
Unknown
Webinar narrator/presenter
That reliance on each other extends to the people Zomedica serves every day. Supporting guiding principle two are people who come from veterinary clinics. Zomedica has six veterinarians and 14 veterinary technicians on staff. They know what a busy clinic needs because they have worked in one. and that experience shapes what we build and how we support it. This is the veterinarian workflow pillar in practice because our products are designed to fit the way a clinic already works. Here's Tanja Buchmann, DVM, Senior Product Manager on Zomedica's Upstream team.
Dr. Tanja Buchmann
Senior Product Manager, Upstream Team
I'm Dr. Tanja Buchmann, Senior Product Manager at Zomedica. Clinics need three things. from the products they use every day. First, results in treatments they can trust. Second, something that fits into a busy day without extra steps. And third, a good experience for everyone in the clinic, the team, and the pet owner. When products get one of those wrong, a clinic feels it right away. That's why we listen so closely to what our customers say. A good example is the VetGuardian Plus monitor. Technicians and veterinarians told us it would help to see a patient's vital signs right at the kennel instead of checking a phone or tablet. So we built a display into the monitor. Now a technician walking by can see the vitals at a glance and even acknowledge an alarm right there. And we looked after our existing customers too. They keep full support and training with an optional upgrade to the new monitor. The feedback from customers who upgraded was that it's more user-friendly for post-op recovery cases and it gives another level of peace of mind when passing by. We listened, we built it, and we supported the customers who already trusted us.
Unknown
Webinar narrator/presenter
That clinical view carries through after the sale, and Halso Medica supports each customer.
Unknown
Webinar narrator/presenter
Here's Nicola Garnett, Director of Customer Relations.
Nicola Garnett
Director of Customer Relations
Hello, my name is Nicola Garnett and I am the Customer Relations Director for Zomedica. I've been with the company since 2017. So the customer said to me, due to the level of care and attention that we gave him on a holiday weekend, he absolutely wasn't even going to consider looking at any competitive devices. And since then, his usage of the Pulsar has increased. He's a very happy customer. That's a sort of story that sticks out in my mind, how he went over and above. and we're obsessed by our customers needs. There's various ways that we stay connected with customers. I feel that Thank you for joining us. or providing new scientific research or any literature they might need and certainly a more personal touch with picking up the phone is definitely something that I believe is very important.
Melanie Schultz
Manager of Customer Support
Here's Melanie Schultz, customer service manager. Hi, my name is Melanie Schultz. I am the manager of customer support for Zomedica, and I've been working in the animal health space for the last eight years. Great customer support means having a knowledgeable, responsive and reliable support team who understands just how busy these clinics are. The customers want timely answers, clear guidance and effective solutions so that they can focus on their patients. They also want to be confident that the products they rely on are supported by a team who truly cares. I instill this mindset in my team by emphasizing accountability and a customer first approach in every interaction. I encourage the team to actively listen, take ownership of issues, communicate clearly, and follow through on commitments. Great support goes beyond just resolving an issue though. It's about building trust, anticipating customer needs, and creating a positive experience that makes customers feel confident working with us. When our team understands the impact our support has on veterinary professionals and patient outcomes, it reinforces the importance of delivering exceptional service every day. I truly believe that every member of the customer support team at Zomedica is dedicated, passionate, and excited about the work that we do daily. They're also very excited about what lies ahead for the company.
Unknown
Webinar narrator/presenter
Serving customers well also takes discipline with every dollar, which is the focus of Guiding Principle 3. With decades of combined experience, Zomedica's finance team brings a broad perspective shaped by work with startups, large public and Fortune 500 companies, and public accounting firms. The team holds CPA credentials and brings experience across controllership, financial reporting, auditing, and risk management, providing a strong foundation for thoughtful, disciplined spending decisions. Here's Mike Zuehlke, Senior Vice President of Finance and Corporate Controller with Jason Westfall, Senior Director of Financial Planning and Analysis. Mike Zuehlke will also present our third quarter results later in today's session.
Jason Westfall
Senior Director of Financial Planning and Analysis
Really focusing on transparency. Where are we spending our money? What's the business purpose for it? How are we doing? And what are we getting for it? Alignment, trying to make sure that the dollars and the spend that we're putting in place is aligned with our strategic priorities and efficiency. Are we getting the best value for our money? So I don't think it's just a finance decision. I think it's a broader collaborative effort. We try to understand the business needs, evaluate the different priorities that different groups have, and determine where we can get the greatest return. And our job doesn't stop there. Once the decision is made on where we're going to deploy the dollars, our group in FP&A helps track, report, analyze. We look at our performance, we look at the trends, and we try to report back on the results that we're seeing and try to understand if it's not where we would have expected it. and some of the significant drivers around that. And then we try to tie that into measurable outcomes. It's not just dollars on a piece of paper, but are we generating more leads with this spend? Are we seeing the revenue growth in the areas we would have expected? Are we seeing cost savings or operational improvements? And so we don't want to just be a group that says, did we stay within the budget? But it's also a level of reporting on what are we getting for the money that we're spending? And that helps us make better decisions, helps us be more accountable. and ensure we're directing those resources in the most efficient manner. One of the things that stand out to me is our performance in selling and marketing expenses. You know, in our quarterly filings and our press releases, we have been mentioning that our sales, selling and marketing expense dollars are going down and the leverage against the revenue that's being generated is going up. And again, that was a collaborative effort. We worked with our sales team, our marketing teams. We assessed our trade show attendance, our use of consultants, our marketing plans for each product and really tried to find and measure where we're getting the best value. And I think that's starting to come through. And that's exactly what financial discipline should look like.
Mike Zuehlke
Senior Vice President of Finance and Corporate Controller
And then I think from a less day-to-day perspective, I think back to our acquisition of Corvo Biotechnologies. I've spoken multiple times on these monthly calls about the scale in which the company has invested and our position to be able to support significant growth within our existing cost structure. At the point in time we made the acquisition of UBT, the size of our existing diagnostics business did not support the acquisition in an obvious way. However, we had the benefit of insight from various leaders within the company, a view on the market opportunity that existed, And when you put that in conjunction with the terms that we were able to negotiate for that acquisition, the case was very compelling. And as you roll that forward, we just released results on November 4th that showed diagnostic segment revenue was up over 100% when compared to the prior year. And that capacity that we bought has also been a key contributor that's enabling us to support the revenue being generated from our development services segment.
Unknown
Webinar narrator/presenter
That discipline protects the investments that matter most, including research and development. Behind guiding principle four is a research and development team with more than 15 years of in-house, hands-on knowledge of our technology. The team pairs that depth with new talent who bring a fresh perspective, and the work ties directly to quality of care of the pet. Ashley Wood led our October session on Zomedica's clinical program. Here's Ashley Wood, PhD, Vice President of Research and Development.
Ashley Wood, PhD
Vice President of Research and Development
Hi, I'm Ashley Wood, the Vice President of R&D at Zomedica. One of Zomedica's greatest strengths is the talent we've built and retained across the organization. As we've grown through acquisition, we've deliberately retained the subject matter experts who developed those technologies, allowing us to leverage decades of specialized knowledge across all of our product lines. At the same time, when needed, we bring in new scientists and engineers who learn from these experienced leaders by contributing fresh ideas, technologies, and perspectives. This combination of deep expertise and new thinking drives innovation and helps maintain momentum across our development pipelines. By pairing experienced experts with emerging talent, we preserve critical knowledge, accelerate development, foster innovation, and position the company for long-term growth.
Unknown
Webinar narrator/presenter
Experience and fresh thinking are easiest to see when they work side by side. Here's Ian Harmon, Senior Director of Research and Development with Ava Schaeffel, Associate Scientist.
Ian Harmon
Senior Director of Research and Development
Working at this for, you know, over 20 years now, and one of the things I really try to bring to my team is just mutual respect for everybody within the team and to have kind of each team member feel comfortable with coming up with their own ideas and interpretations of things. Kevin Russell Klass, After they've tested it, we'll kind of review the data together as a team and talk about next steps. And especially with younger employees, I definitely try to get them to go ahead and try to come up with what the next steps are and just come up with their own ideas on how to solve problems.
Ava Schaeffel
Associate Scientist
Yeah, I've definitely felt that coming into the team. What drew me to Zomedica, other than just I really like the type of science and research that we're doing here on this R&D team, I also really liked the people. I had an interview with my boss, Cyntheron. and he was pretty you know asked some hard questions but it was also pretty informal and just wanted to see what I wanted out of the job and then I met Ian and it was really similar and I came in and I actually commented how there was something written on the whiteboard that day that was different than the previous day and then Ian was like oh let me just explain exactly what's going on right on this whiteboard too and so it's just a team of people who really want to make sure you understand what's going on and do want to hear your new ideas and I think being a fresh mind on the team it's It's been good to just be able to ask questions, not only for my learning, but to say, hey, is this the best method for analyzing this? Why are these your thresholds? And it allows me to learn and also challenge the people around me to keep doing what they're doing and doing it as well as they can.
Ian Harmon
Senior Director of Research and Development
So right after Ava started, we really just kind of threw her into the deep end on one of the assays we're working on. And we were having some technical issues with that assay and Ava jumped right in with both feet. and spend some time in the lab troubleshooting things. So I was able to use my past experience with what has worked well with other tests we have developed and my knowledge of the platform in general to make some suggestions. And then Ava really stepped in and was able to use her observational skills and fresh ideas to help us improve the test we were working on.
Ava Schaeffel
Associate Scientist
Yeah, it was a lot of time where I was in the lab and would be able to, with my boss as well, report back on what we were observing. and then bounce around ideas on what might need to change. And then Ian's a tech whiz with the program that we run for the assay to run. So just making small tweaks there to get a change that led us to having better precision so far.
Senthuran Akputunathan
R&D Manager
Hi, my name is Senthuran Akputunathan and I'm an R&D manager at Zamerica.
Multiple speakers
Senthuran Akputunathan and Michael Newton
I have over 12 years of experience in biotechnology and diagnostic product development.
Senthuran Akputunathan
R&D Manager
Recently, we were developing a new assay and faced some challenges with precision, background signal and overall assay performance in sample. This helped us identify the right conditions to improve assay performance and move the development closer to verification and validation. Ultimately, our goal is to develop a reliable test that helps veterinarians make better decisions for their patients. I truly believe collaboration needs to start early. Research and development focuses on developing and optimizing the technology. Manufacturing makes sure the process can be reproduced consistently on a larger scale. And the product team helps us understand what customers need. My role is to bring these teams together and help move an idea from development to testing and production. For me, it's knowing that the work we do helps veterinarians make better clinical decisions. Developing reliable and accurate diagnostic tests can help identify the health issues earlier, monitor disease progression, and ultimately improve patient care.
Unknown
Webinar narrator/presenter
Our manufacturing team then builds what R&D designs, consistently and at quality. Zomedica's Georgia operation in Roswell was built in-house, from the ground up. 20% of the employees there have been with the operation for more than 10 years. They know how to make these products in ways that take years to learn, and that knowledge stays inside the company. Michael Newton was there from the start. Here's Michael Newton, Manager of Manufacturing.
Multiple speakers
Senthuran Akputunathan and Michael Newton
Hello, I'm Michael Newton, the manufacturing manager here in Roswell, Georgia. I've been with the company a little over 15 years. When I started, we were a very small operation, probably six or seven of us, and we were focused on the pulse deck. Now, we moved into the facility that we're in now in the fall of 2022, and we had a really simple idea just to build the best quality of products that we could. And we thought that was twofold, to hire a great team and then also to make the facility suitable for that task. So through our own sweat and muscle, we built a facility that we think we can be proud of. And we continue to expand our team with good people for the expanding products that we have. And that is really how we built the Georgia operation from the ground up. Since we have a variety of products, learning the intricacies of each device can take time. But even more than that, bringing the Zometica standard quality to our devices can take time. Thank you for joining us. During the manufacturing process, we would always check the device to make sure that it was working right and that everything was good. And then we'd check again. And then we would check again. And we called that the triple check of manufacturing. Now that was instilled in me by the first engineer that was hired, which was Robert Biggs. And I carry that still with me. And I impart that on our employees now. So we triple check, triple check, triple check every device along the way when we're building devices. And so we want to maintain that standard of quality. And I think that's how I have instilled the culture of quality on the manufacturing floor.
Unknown
Webinar narrator/presenter
That experience on the floor shows up in every product that ships. Here's Brian Dickerson, Senior Director of Manufacturing with Maddie Rickert.
Maddie Rickert
Manufacturing team member
So one quality aspect that we ran into on our line. So we host a cross-functional meeting to look at field errors and discuss what we should do about them. We saw a consistent error that kept popping up that had to do with the electrical component of our cartridge. And we added an electrical testing into our manufacturing line. to kind of catch these parts that we're going through. It wasn't a huge quantity, but we have over the last few months been able to catch and remove on average 0.7% of cartridges. It sounds like a small amount, but that's over 600 parts that would hit the field and result in an error.
Brian Dickerson
Senior Director of Manufacturing
Yeah, the error that Maddie was talking about that we're experiencing in the field. That, you know, we feel very fortunate that we were able to, you know, diagnose really what was going on, what was causing that. And then we were able to implement it in our assembly process right away. It was just a good example where we took field data, applied it back to our manufacturing operation, and then came up with a novel, easy to implement solution and now we're better off for it. Anyway, I think the long experience in the manufacturing line, it encourages a sense of ownership with the product and the process and the feeling when you have that ownership in your work, it promotes efficiency and improved quality. At Zemedica, we've been blessed with a strong technical staff to help support us in manufacturing. Our R&D, engineering, and QC teams are top-notch. They support us with all the day-to-day issues. They also help us with the successful introduction of new products. Many of our technical staff have been with this technology since its beginning, so we have a long history with that to rely on to help us with any sort of manufacturing issue. On the manufacturing side, several of us in leadership positions have long histories of manufacturing experience, myself included. All manufacturing operations deal with the same issues, such as supply chain management, proving yields, cycle times, cost improvements, hitting your daily shipments to customers. And having this experience means you already know what needs to be done, and you already know how to go about doing it. and manufacturing is all about keeping up a cadence to help keep the factory output consistent. Manufacturing operations run best when people know what's expected of each day and also to keep the cadence up so that they run consistently at a constant rate. To this point, we've instituted daily huddles a few years ago. They're attended by all necessary functional groups so that everyone in the organization knows what's expected on that particular day. In addition, it's vital that we continue to strengthen our manufacturing operations going forward by providing quicker information that is needed to help grow our factory output.
Maddie Rickert
Manufacturing team member
Just focusing on our manufacturing floor itself, when we have a lot of experience out there, we're able to respond quicker to issues. We're able to support engineering more by really learning the equipment. and just have more eyes on our product and the quality of it. And I think that that's important for experience out on the floor itself.
Tony Blair
Chief Operating Officer
I'm Tony Blair, Chief Operating Officer of Zamedica. By manufacturing in-house, we've created competitive advantages, including greater control over our product quality, our production processes and timeliness, which I define as speed to results. It allows our company to respond quickly to customer demands, make improvements more easily, Thank you for joining us. Product Reliability and Product Performance. We see it in every aspect of our operations, from the materials we source and the products we manufacture to the processes we follow and the services we provide. It is built into our daily activities through our attention to detail, following consistent proven standards, and a commitment to continuous improvement. Each team member plays an important role in maintaining quality, ensuring that we deliver reliable products, meeting our customer expectations, and we take pride in everything we do.
Unknown
Webinar narrator/presenter
Once a quality product is built, it still has to reach the right veterinarian, and that is where Guiding Principle 6 comes in. At every major veterinary conference, attendees walk past dozens of companies competing for a few minutes of their time. Earning that attention takes creativity. Zomedica's marketing team designs each touchpoint, from the trade show booth to the digital campaign, to spark curiosity and start a real conversation with veterinarians. That creativity starts with choosing the right rooms. Here's Susan Jenkins, Senior Manager of Marketing Services.
Susan Jenkins
Senior Manager of Marketing Services
and our sales reps prospect locally, personally inviting veterinarians in the region to come experience the technology hands-on. And at the show, KOL lectures on the science drive attendees straight to the booth, where promotions and giveaways keep the conversation going. Everything we do leads with the science and the real clinical needs our products solve. AAEP is the perfect example of marketing driving results. Our product marketing team worked tirelessly with the show organizers to secure multiple lecture spaces and a wide range of promotions, both at the sponsorship level and in the new product section. Product marketing built strong campaigns before the show to create buzz and kept the momentum going after it. Marketing then equipped our reps to personally invite potential customers and positioned our KOLs to lecture on the science behind why veterinarians need our products, then stopped by the booth to talk about them in person. Every piece worked together and it proved out in spades, producing multiples in sales far above our spend. That's marketing, trade show, and sales working together at its finest.
Unknown
Webinar narrator/presenter
Creative work is most effective when it is aimed in the right direction. Zomedica's marketing team pairs creative strategy with data, using new tools to learn which messages, channels, and audiences drive engagement. Clear goals, intentional choices, and creative execution are what turn a veterinarian's curiosity into a conversation with our sales team. From there, Guiding Principle 7, a tenacious sales approach, turns that conversation into an account. Guiding Principle 7 is carried by people who come from across animal health. The sales team brings deep experience from across the animal health industry with diverse backgrounds that provide a broad understanding of the veterinary market, our customers, and their evolving needs. They know the customer, they know the competition, and they understand that a not now is often the start of a sale.
Unknown
Webinar narrator/presenter
Here are some members of Zomedica's sales organization, Kelly Berry, Eric LeBeau, and Brandon French.
Kelly Berry
Capital Equipment Specialist, East Coast
Hi, I'm Kelly Berry. I've been an account manager in New York City for almost two years and was recently promoted to the capital equipment specialist for the East Coast. Before Zomedica, I worked at Covetris. What I learned is that products alone rarely differentiate a company. What sets you apart from the competition is understanding a clinic's goals, delivering unmeasurable value, and becoming a trusted partner in the clinic success. In my territory, Tenacity means consistently building a robust pipeline Identifying opportunities and showing how Zemedica's therapeutics and diagnostics work together to enhance patient care while supporting practice growth. One example is sheltering vets. I started by scheduling a VetGuardian Plus refresher training to help maximize utilization. As the relationship grew, I learned that they had recently purchased a laser. Unfortunately, the cases they were seeing were not responding to just laser alone. Instead of trying to replace their investment, I introduced PulseVet shockwave therapy as a multimodal approach to chronic wound healing and pain management. Within a month of purchasing the device, they saw significantly improved outcomes, and today it is a key part of their treatment protocol. At Zomedica, we're not just selling devices, we're selling solutions to real practice problems.
Eric LeBeau
Account Manager, South Texas, Central Region
Hey everyone, Eric LeBeau, Account Manager, South Texas, Central Region. My experience with HESCA, Quattro, and Zometica has given me a strong understanding of the animal health industry and what it takes to succeed in a competitive and evolving market. Throughout my career, I built my success on persistence, relationships, and understanding the challenges that veterinary professionals face every day. At HESCA and Quattro, I developed a strong foundation in capital equipment sales, navigating complex sales cycles, building territories, and earning the trust of veterinary teams. I've continued expanding that experience by introducing innovative technologies and helping practices recognize both the clinical and financial value of their investments. The animal health market requires persistence, consistency, and what has made me successful is my ability to engage with our customers, build long-term relationships, and make sure that I'm a true value asset to their team as well. Main Street Animal Hospital presented a significant opportunity really for me to rebuild a relationship Through persistence, relationship building, and rebuilding our credibility, I earned their trust in demonstrating the improvements and upgrades and updates to our VetGuardian Plus that they decided to give us another try. That went really well, and that trust helped open the door to the rehab and ortho team I'm Brandon French, the Senior Sales Director for the Central Region at Zomedica, where I've been for slightly over four years.
Brandon French
Senior Sales Director, Central Region
My career in animal health care spans 36 years with almost three decades of leading and growing sales organizations within the industry. Before joining Zomedica, I spent years leading sales organizations in the veterinary diagnostic and imaging space with companies like IDEXX Laboratories, Universal Ultrasound, and Oncure Partners Ultrasound and Telemedicine. And this kind of gave me a front row seat to how veterinary practices work. And working at this level also taught me that veterinary practices just aren't buying a piece of equipment. They're investing in workflow efficiency and clinical confidence. Since veterinarians are under immense time pressure, If a technology doesn't really fit into what they're doing or work on their day to day, it just doesn't get used. And that's not good for us or the practice. As for the competition, you know, the larger companies with their legacy players often rely on their size and bundled contracts to try to drive their sales. But this also showed me that there's an opportunity for a company like Zomedica. When you lead with innovation, technology, and support, you're really helping the clinic themselves drive better value for their practice. A great example was a large multi-doctor practice in the central region that one of my reps had been working for a few months. They lacked the clinical science behind the PulseVac technology, but the managing partners were somewhat hesitant about moving forward because they were concerned whether they could really make the device pay for itself or not. And after the rep going in several times and meeting with the actual doctors, you know, we just weren't really seem to be gaining much ground with it. So we scheduled a meeting just to meet with the actual practice manager and one of the managing doctors. And what we asked for is them to give us the caseloads they thought they would see on a monthly basis that they could use PulseFed for. So taking those numbers and cutting them in half and using our ROI calculator, we essentially showed them they were at the device paid off in about seven to nine months. So when they step back and say, okay, when seven to nine months, this has paid off, it made much more sense to them. And after we had that conversation, we were able to move to a close within the next 30 days.
Unknown
Webinar narrator/presenter
Those are Zomedica's seven guiding principles. And these are the people who live them every day.
Jason Westfall
Senior Director of Financial Planning and Analysis
I am Zomedica.
Unknown
Webinar narrator/presenter
Next, Mike Zuehlke, Senior Vice President of Finance and Corporate Controller, will walk through Zomedica's third quarter 2026 financial results.
Mike Zuehlke
Senior Vice President of Finance and Corporate Controller
Good afternoon, everyone, and thank you for joining us today. We appreciate your continued interest in and support of Zomedica. Today, I'll walk you through another strong quarter for Zomedica. We achieved our 23rd consecutive quarter of record year-over-year revenue, while also making further progress on the two objectives I've highlighted since taking on the role of discussing earnings with you all. Reducing our cash burn, and moving closer to cash flow breakeven and adjusted non-GAAP profitability.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
What stands out about this quarter is the combination of growth and improving financial efficiency. Revenue continued to advance. Operating expenses continued to decline. As a result, cash consumption moved lower. Together, these trends reflect the progress our actions are making in creating a more efficient business while continuing to generate impressive growth. Revenues for the Corp increased 22% year-over-year, and they were supported by three key contributors. First, demand remains strong for our pulse vet and CCE health in both the U.S. and Canada have helped support adoption, while our expansion into additional initial territories is extending our reach into new markets. Third, our development services segment continues to make meaningful contributions, generating another $1.1 million in revenue during the third quarter. Beyond revenue, we also saw progress on the cost and profitability side of the business. Our operational results highlight that progress. Gross margins remained healthy at 61%. Operating expenses declined by $2.6 million for 22% compared with the prior year. Through the third quarter of 2026, the year-to-date loss has improved 60% compared with the same period in 2025. Cash for a decline by $1.5 million, a 32% reduction from the third quarter of the prior year. These results are important not just in isolation, but in how they work together. We're growing the business while managing our cost base effectively. and that combination is central to our path toward break-even and profitability. As we look ahead, our priorities are consistent, but not consistent on turning our existing commercial momentum into sustained financial performance. That means acceleration of good action across our global performance, expanding commercial partnerships, continuing contributions from development services, and our strong balance sheet provide a solid foundation for the remainder of 2026 and the end. Our focus is on translating that foundation into sustainable growth. Continued operating efficiency and growth of long-term shareholder value. With that overview, let's take a closer look at the drivers behind our results, beginning with revenue. Total revenue for the third quarter of 2026 was $9.9 million, up 22% from development services. Core products, which encompass our diagnostics and therapeutic devices segments, Thank you for joining us. Great utilization of our expanded SA menu supported this performance. Notably, development services continued as an important contributor to another $1.1 million revenue coming through this quarter from the year-to-date total of $4.5 million. We remain committed to the pursuit of strategic opportunities that leverage our existing asset base and scale to drive incremental value for our shareholders within both the animal and human health sectors. Consumables revenue across all segments increased 26% for the quarter and dropped 25% year-to-date. Thank you for watching. As we extend our presence into additional markets and strengthen our commercial reach, we believe international sales will become an increasingly important contributor to long-term growth. Turning out operating expenses, we continue to work on aligning our cost structure with the scale of our business. Thank you for joining us. We have improved 68% year-to-date, reflecting our commitment to discipline cost management and the realization of the scale in which the company has invested. We anticipate a continued operating leverage as sales continue to grow across all segments, and this growth is supported by our current cost structure. Looking at the individual expense categories. Looking forward, R&D spending may increase moderately as we continue developing next-generation products and pursuing solutions for unmet and underserved market needs. We will continue to balance expense discipline with the innovation needed to support future growth. Thank you for joining us today. Our takeaway is that expense reductions are occurring across all three categories. We intend to maintain a high discipline while ensuring we have the resources necessary to support our commercial opportunities and longer-term product development. Turning to the balance sheet, Zometica ended the quarter with $40.9 million in cash, cash equivalents, and available for sales securities. Cash used during the quarter was approximately $3.2 million, representing a 32% reduction compared with the third quarter of 2025. This was our lowest third quarter cash earned on record. The improvement extends beyond the quarter itself. Year-to-date cash-earned operating results, the direction is encouraging. We are generating more revenue, maintaining healthy margins, and reducing operating expenses. Thank you for joining us today. Our third quarter results reinforce our confidence in the progress that is being made. Revenue growth remains the key driver, but the amount. Again, thank you for your continued interest and support of Zomatica. And with that, I will take the turn of the presentation over to our CEO, Larry Heaton, for his remarks. Larry? Hey, thanks to the team.
Larry Heaton
Chief Executive Officer
Thanks to everyone who shared their work and their perspectives today, including, of course, Kristin Domanski, who introduced our guiding principles, and Mike Zuehlke, who recapped our financials.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
What you heard today is how we operate every day.
Larry Heaton
Chief Executive Officer
We will be enjoying Thanksgiving on the fourth Friday as the day after, I should say, as you all will. And then in December, we'll take a break and start up again in the new year.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
Please feel free to reach out with any questions that you might have or comments or just to have a discussion. So for now, we appreciate your time and your interest in Zematica.
Unknown
Webinar narrator/presenter
Questions later, you can contact us with the contact information shown on your screen.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
Okay.
Larry Heaton
Chief Executive Officer
So thanks to everyone who has participated and thanks to those who are attending today. Before we get into the info, I'd like to share with the group. Within the next several weeks, in addition to the three new equine assays for our Truforma device, our Truforma immunochemistry shortly, in addition to those, we will also be launching several new products in both of our operating segments, both therapeutics and diagnostics.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
which is the American Association of Equine Practitioners meeting in early December and then again at the large Small Animal Conferences VMX February.
Larry Heaton
Chief Executive Officer
These products represent both evolution of our existing technology and also expansion of products within a segment. We'll be providing additional news and information to the market and certainly before the December 7th start of the AAP meeting.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
So,
Larry Heaton
Chief Executive Officer
With that, I will jump to your questions. So let's see, we have a few. Can you say more about human health opportunities and explain generated revenue by this segment? We are partnering and collaborating with a couple of companies, several companies, I should say. One, we disclosed as we entered into The bulk of the revenue we generate from them is for manufacturing their devices. We also do some fulfillment and some support over the year. The manufacturing revenue comes in given quarters when they place orders for additional devices. And that's pretty straightforward. We have a couple of others that we're working with. The other is one that we haven't disclosed to the partner out of consideration for the fact that they are Thank you for joining us.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
Thank you for watching.
Larry Heaton
Chief Executive Officer
You can see it's sort of a steady state in terms of revenue. In some quarters, it's higher. And those would be the quarters where we manufacture devices to put into the clinic or we manufacture devices from. We expect this revenue to continue pretty much the same steady state. You know, then we would expect an uptick. and as they launch into the market, then that's an exciting opportunity for them and frankly for us as well. Thank you for joining us. I think Truforma might have a bit of an edge simply because it's a very fast growing. It certainly has 113% year over year.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
And so it's certainly the highest percentage growth, but also the revenue is adding up pretty nicely.
Larry Heaton
Chief Executive Officer
and as we continue to add to assays and capital money to leverage our relationship with Boringville-Inglheim, both in the United States and Canada and potentially in other countries as well, we think that might have a little bit of an edge. But, you know, Pulse Fed's not given up the lead position in terms of revenue growth. It's close behind. and then beyond that we have new products that we just talked about that we'll be launching over the next several weeks and we expect a significant revenue. Most of those cases will be off of a zero base so it'll be a high percentage growth but also will be meaningful revenue and that's not to count out the other products as well which which are all doing very nicely without major new costs. The good news there is we've invested in the infrastructure in our Atlanta area facility and our Minneapolis area facility and both our electromechanical in Roswell, Georgia, as well as our biotech facility in Plymouth, Minnesota. Both of them can basically produce about five times current revenue without any additional investment. We might have to add another shift or hire someone else because we have so many orders going out the door or what have you, but no additional investment to be able to do those.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
So that's good news.
Larry Heaton
Chief Executive Officer
How we deploy your $41 million liquidity across global expansion human health opportunities and acquisitions while minimizing shareholder dilution. So it's efficient capital to grow to gap profitability. without raising any additional, without needing any additional, basically working capital. And as I mentioned before, we expect to be cash flow positive in this current quarter, a little bit. And we expect to be cash flow positive for the full year of 2027, which would then tell you that we'd still be right around that amount of capital.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
And the products that we need, our sources, all of that money has essentially been expended.
Larry Heaton
Chief Executive Officer
and those that we are bringing in from a partner, from OSTS, and that is the sort of standard that we'll carry forward into the future as we add new products in the out years. While we expect that we work, then that wasn't a setup. Those are actual conversations about the fact that we're squeezing every dime to get quarters out of it.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
A reason why.
Larry Heaton
Chief Executive Officer
And so I will say that from a personal standpoint, what I just told you about the product launches that we've anticipated, not the assays, but advisors and legal counsel, none of those individually have risen to the level of materiality which would require disclosure. and so technically I would have been in because our window is open. However, me personally, I have felt a certain kind of way about purchasing stock in the open market when I know that we have these products that we're about Now I have shared that with you. So now I have no compunction whatsoever about taking advantage of a very attractive share price. And I hope that answers your question. I get into trouble every time I answer these questions from counsel, so let me just leave it at that. Another grandchild might be on the way. Knock on wood.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
I know my wife is really looking forward to it. Let's see here. What is the quarterly... Let's see. There was another one at the top here.
Larry Heaton
Chief Executive Officer
Zolotic has invested significantly in expanding specific milestones. I think the rest of that question is probably, would you look to see how you're doing?
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
And I think there was another question here. Let's see if I can find it. Okay. Basically, what are the major KPIs in those ones together? Actually, one more. What is the quarterly revenue estimate to... Here we go. What are the key milestones in the timeline for sustained positive cash flow adjustability and eventual gap profitability? Cash flow positive and gap profitability. Mike, do you want to take that? Thanks, Larry. I guess kind of knocking on the door here, going to the first one in terms of assessing... The investments made in therapeutics and the diagnostic services business and how to assess them to focus primarily, not solely, but with a heavier emphasis on our consumables revenue. We've spoken, you know, on these webinars of our Race Your Life model. Consumable revenue growth is an indicator of both increased utilization, which is fantastic, and we want to see from all of our users, or additional device placements, so a larger customer pool that we have to buy the recurring products. All segments was up 26% quarter over quarter, year over year. Last way I would look at it from an external point of view, If I look at our consumables revenue as a percentage of total revenue, excluding the engineering revenue, I'm going to carve that out because there's only six versus three months in the 2025 numbers. So we exclude that. Consumables revenue represents 76% of our total revenue. year-to-date. That's up from seven. It's continuing, recurring, right? It's not the one-shot drink of a capital systems purchase. So I think that speaks to the success of the investments in our two course segments. As to the question around quarterly revenue estimates to cash flow rate even and gap profitability, quarterly, just capital equipment by nature, large outlays of cash can be choppy in the way we see demand come through. We also tend to see a spike in Q4 as that present themselves at the end of the calendar year and making capital purchases. But I think more broadly, we've been consistent in saying and still hold to the fact that 50 to 55, closer to 50, or at 50, is an annual revenue number at a healthy margin. that we expect to be adjusted non-GAAP EBITDA profitable. Obviously, Gap Profit comes a little ways down the road. Larry laid out the timeline, right? We have a plan in place. We anticipate cash flow positivity in the fourth quarter of this year, and we expect cash flow positivity. Thanks, Mike. There's one with the improvement status on Canadian sales. We don't break that. As you heard from my Canadian sales, but also very strong sales from Europe and we have good sales from South America and so on.
Larry Heaton
Chief Executive Officer
So all that's going well. I will say that Canada, we know from over the last year we introduced our products through a new distributor in Canada, and they're doing very nicely. And then our Born from Lime collaboration in Canada was terrific, or is terrific, I should say.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
I mean, I'm very sure by the lack of, you know, the backward, the New York Animal Hospital,
Larry Heaton
Chief Executive Officer
I don't have any specific percentages, but we've been super pleased with how that has gone and is continuing to go.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
That's a pretty good question.
Larry Heaton
Chief Executive Officer
It's not one that we have. Well, first of all, with the exception of the Aztec loop, all the other products are used by veterinarians and it just wouldn't be appropriate to put them in a and one of these retailers. So chosen to go is through the online vendors that most pet parents today use like Chewy and Petwishes from Walmart products through those channels as well as through our own Shopify site.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
I do think that we have We have potentially put it in some tractor supply stores, but a major contributor at this point.
Larry Heaton
Chief Executive Officer
And some of the specialty equine shows now, there are vendors that are... and so on and so on. So a lot more products in the retail market we would probably go down that road.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
But at this point I think a lot of those stores are not doing so well because of the online versions. Let's see.
Larry Heaton
Chief Executive Officer
So we'll have to see more data and graphs as part of these briefings. I think we've done that, you know, pretty well with respect to some of these webinars.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
As they do the earnings in the future, we can show, you know, a graph that shows the steady progression of revenue and things like that. It's easy enough to do and we'll do that.
Larry Heaton
Chief Executive Officer
How many Truforma instruments are actively in use? How many were added in use? So I think there's probably plenty of people on the call that could answer to the first two of that, which is, I've got to disclose that information for competitive reasons, sorry. But in terms of the health path revenue, Thank you for joining us. Any strategic thoughts with combining with other animal health companies?
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
Sure. You know, all the time. The trick is to not be the sort of valued.
Larry Heaton
Chief Executive Officer
And so from our perspective,
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
We have near-term milestones, cash flow break-even in the current quarter, cash flow positive and adjusted to be positive. It's been ourselves a chance to realize these milestones that we see that we continue to execute towards.
Larry Heaton
Chief Executive Officer
That puts us in a much better position to be on a better standing. The short answer to that is
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
You know, any overtures or any solicitations, you know, beyond the fiduciary responsibility, it's always good business anyway, to look at how, as I just mentioned, in addition to expanding or to formalize with additional assays, and, you know, those are going to take us to where we really want to go. So there's a few questions about buying shares back. Do we have a share buy? And just so you know, if the board ever does authorize a share buyback, that would be signed on a press release as well.
Larry Heaton
Chief Executive Officer
So you would know it within two business days or something like that of it being approved. However, we do not have one authorized at this point. We do not plan on buying back shares until we are cash flow positive.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
And so that is why we believe we have sufficient capital to achieve all of our objectives. The last thing we want to do is to
Larry Heaton
Chief Executive Officer
Use some of that cash. It's certainly tempting, I will say that, at these levels in terms of pricing. But the responsibility is to the business and to all shareholders to impact on the share price so we don't give up an opportunity to make sure that we're successful over the long haul. So here's somebody that likes the shirt that I have on. Let's see here. I think you saw some of the other people supporting one as well. How can I get that one? Let me look into that and we'll see if we can scare one off.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
That was Q4 shaping up very nicely.
Larry Heaton
Chief Executive Officer
So I think it's important by the take of existing products into the capacity you are spending on.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
Now, when we built out the facility in Atlanta, we didn't do anything.
Larry Heaton
Chief Executive Officer
Thank you for joining us. and all of that. We're looking to build a very significant, substantial company to build a company so that it can then ultimately reflect the kind of shareholders expect as well. So we intentionally built that facility so that it did have the capacity to grow. We acquired the Corp facility, the former Corp biotech facility, and there, you know, the manual assembly line to make the cartridges was not something that was going to sustain substantial growth. And so we invested, it was about $6 million to the line, which I think you've seen in our manufacturing webinar, and That can grow. So we did it to ensure that we had quality manufacturing. We had lower cost manufacturing. That was one of the things we needed to do. And so we're not disappointed in the take of a product. Of course, we always wish it could be higher. We could grow faster and so on and so forth. But the kind of growth that we're We're pretty pleased to last two or three quarters. We're up there. I even saw on LinkedIn, there was someone that did an analysis of the top 10. 12 animal health companies. And it pleases punch for us to be included in that list. Even more pleased with the fact that at that point in the snapshot in time, we had the highest growth rate of any of them. So it can always be better, but as a long history and track record, that particular product into the small animal market was essentially a startup. It just has been really all of our other products, especially Truforma and the rest of them. So it was an intentional plan. So we're pleased by that. What happened to the results of the annual meeting regarding that whole thing was about what if we don't get a quorum at the first meeting, you know, at the annual meeting? Under the old scenario, you just have another meeting, a second meeting, you have a third meeting, and a fourth meeting, and it just goes on until you finally get a quorum. The amendment to our charter We have a second meeting and then whatever additional people show up or additional shares show up to be voted in addition to the ones that were at the first meeting, then that will be considered a quorum and you can go ahead and conduct the business. But it was approved, and as it happens, our most recent annual meeting, we had well over what we needed for a quorum. So it's just a good bit of housekeeping, and it was suggested by Mike and Karen, our general counsel, and it was, I think, for many shareholders, and many of them don't have that many shares, and if they just didn't show up, then we wouldn't be able to conduct the company's business at the annual meeting. How extended is the company as far as distributing products internationally given the general profitability issues? If the question is, are we spending a lot of money to expand our international business, the answer to that is no. Look at one of the international market webinars that we did. They're all up on the website. but you can see that we've taken a very low capital. We've had only our PSV or our professional services veterinarian that's based in, always has been based in Switzerland to provide clinical, you know, As we have expanded our product line and have seen a greater opportunity beyond just also that free line, we did make a move to hire a VP of International, as many of you know. So beyond that, we're not putting boots on the ground. We're not setting up facilities, things like that.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
So we're not extending ourselves from a cash standpoint that people in international markets are looking to acquire. Let's see. Is there any potential catalysts coming down the pipe that could move the price to the near term?
Larry Heaton
Chief Executive Officer
Tough to answer, especially the answer with the R6, which you're all familiar with. We have three new true format assays that we have announced previously will be launching here shortly. We've said by the end of the year, and that's coming up in the next couple of years. I also just announced that we'll be introducing several new products in both of our segments, some of which are internally developed and represent an extension or an evolution of existing technologies. And I think some of you maybe have, you know, Thank you for joining us. Thank you for joining us. And in 2018, we would look to then get to the next milestone, which would be gap profit. We believe that those would have some impact on the share price, as concerns about whether they run out of money or things like that would be alleviated.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
The current market conditions will affect your current sales and growth. As much as anyone can know, I just say no.
Larry Heaton
Chief Executive Officer
You know, who knows what will happen in the market. But our products are for when you're a dog, when you're a cat, sick or injured pet to the vet.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
Thank you for watching.
Larry Heaton
Chief Executive Officer
on certain companies in the space. You know, if I was making really fancy expenses in another line that was less expensive, but still good quality dog food. But in our case, it's when they're sick or injured.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
I don't see any impact.
Larry Heaton
Chief Executive Officer
And I think even, you know, we've seen ups and downs in the market from a share price standpoint of our company. It's barely moved in concert.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
So I think we're good there. Employee headcount right now.
Larry Heaton
Chief Executive Officer
140. 140 it is.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
Is there a path forward to have some Medicare reposted on a major stock exchange? There's always a path forward.
Larry Heaton
Chief Executive Officer
That path is meet all of the criteria for a given exchange. And if you look at the various exchanges, the better ones are the most The ones we would see the most, those criteria we'd meet all of them. In order to get the share price up, we'd have to have a whole lot of patience to be able to continue to grow organically, which is our current plan. But at some point in the future, you know, post break-even, post Thank you for joining us.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
and we're committed to working the problem, if you will, until we can do something that the shareholders of the company would support. And I think that is the last of the questions. So unless anyone has any other ones they want to pop in right now really quick, I think with Zelenica that participated, and you all could have turned your cameras on so they could have seen your smiling faces, but okay. But thank you for those that participated.
Larry Heaton
Chief Executive Officer
And I wish all of you a very happy Thanksgiving. We're looking forward to some really exciting stuff. Please follow our news releases in the next few weeks and after the turn of the year.
Multiple speakers
Primarily Larry Heaton and Mike Zuehlke
And we look forward to getting that order and can comment more on Thank you for watching.